Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MediciNova, Inc. (MNOV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.4900+0.0200 (+0.81%)
At close: 04:00PM EDT
2.6000 +0.11 (+4.42%)
After hours: 07:59PM EDT
Advertisement

MediciNova, Inc.

4275 Executive Square
Suite 300
La Jolla, CA 92037
United States
858 373 1500
https://www.medicinova.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Yuichi Iwaki M.D., Ph.D.Co-Founder, Pres, CEO & Exec. Director777.7kN/A1950
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.Chief Medical Officer & Director564.13kN/A1966
Mr. Douglas G Paulin CPA, CPAChief Financial OfficerN/AN/A1976
Dr. Federico Gaeta Ph.D.Chief Scientific OfficerN/AN/A1952
Dr. David H. Crean Ph.D.Chief Bus. OfficerN/AN/A1965
Mr. John O'Neil CPAControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Corporate Governance

MediciNova, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement